However, I wouldn’t buy the shares after the recent parabolic rally, typically followed by a significant pullback. HTGM shares remain quite popular among investors as over 19 million had changed hands at writing and the buying momentum was still robust. The company plans to present data from the above process tomorrow, including the outcomes. HTG revealed that it was applying RNA profiling within its transcriptome-informed drug discovery process and had discovered differential regulation of the ferroptosis pathway by structurally similar compounds that target mTOR. Investors are looking forward to Dr Spitale’s presentation, which is bound to have a lot of new information regarding the use of RNA profiling in drug discovery. The company will be represented by key opinion leader (KOL) Dr Robert Spitale, PhD, from the University of California – Irvine. Most people expect the company to present breakthrough results backed by its innovative processes, which explains the two-day rally, which is likely to persist until tomorrow after the presentation. HTG will also present results from applying its transcriptome-informed drug discovery process. So, the question is, why did investors react so positively to this announcement? The simple answer is that apart from discussing the use of RNA profiling in the drug discovery process to understand mechanisms of action better and refine drug screening. The bullish momentum continued into the premarket trading session today, where the stock surged over 200% before retracing some of its gains. The announcement on Friday triggered a 117.57% rally in HTGM stock as investors eagerly anticipated the event. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines.800+ tradable assets are available for CFD trading in forex, shares, indices, commodities and cryptocurrencies. On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that ’s writers disclose this fact and warn readers of the risks. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |